Skip to main content

Matilde Lleonart Pajarin

I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London.

Institutions of which they are part

Head of group
Biomedical Research in Cancer Stem Cells
Vall Hebron Institut de Recerca

Matilde Lleonart Pajarin

Institutions of which they are part

Head of group
Biomedical Research in Cancer Stem Cells
Vall Hebron Institut de Recerca

I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London.

My Research Group was recognized as an Emerging Research Group in 2009 by the Generalitat de Catalunya and later in 2014 as a Consolidated Research Group.
Throughout my career I have been involved in cancer research from a more molecular point of view correlating key mutations in oncogenes and tumor suppressor genes with anatomical, pathological and clinical features of patients' tumors and also through cell culture studies to determine important key cell signaling pathways in tumorigenesis.
Currently, the main lines of research of my Research Group focus on the identification and characterization of biological mechanisms in resistant cancer cells, including cancer stem cells, to unravel the pathways responsible for their resistance in breast, lung and head and neck cancer models.
In addition, we are particularly focused on identifying molecular targets in resistant cancer cells and cancer stem cells affecting particularly aggressive tumors. The aim is to attack them pharmacologically in order to propose new cancer therapies: new drugs and/or drug combinations to combat resistant tumors in mouse models.

Research lines

Estudio de proteínas de unión a RNA como nuevos factores pronóstico y diagnóstico en cáncer

En nuestro laboratorio hemos efectuado diversos “screenings” genéticos para detectar nuevos genes implicados en proliferación celular in vitro que además poséan un papel relevante en cáncer humano. De entre ellos descubrimos la proteínas CIRP, la cual hemos descrito como proteína oncogénica. Actualmente estamos valorando la función de CIRP en diversos tipos tumorales en correlación con la evolución clínica de los pacientes.

IP: Matilde Lleonart Pajarin

Projects

Ayudas Margarita Salas

IP: Matilde Lleonart Pajarin
Collaborators: Yoelsis Garcia Mayea, Judit Álvarez González
Funding agency: Ministerio de Universidades
Funding: 0.01
Reference: MIU/M_SALAS/2021/GARCIA_UB
Duration: 01/04/2022 - 31/03/2022

Novel terapéutic approaches against COVID-19

IP: Matilde Lleonart Pajarin
Collaborators: Marina Bataller Fernández, Almudena Sanchez Garcia, Yoelsis Garcia Mayea
Funding agency: Fundació La Marató de TV3
Funding: 161875
Reference: 202116
Duration: 23/09/2021 - 22/09/2024

New therapeutic approaches in head and neck cancer

IP: Matilde Lleonart Pajarin
Collaborators: Yoelsis Garcia Mayea, Jordi Temprana Salvador, Angel García Jiménez, Josep Castellví Vives, Laia Josa Culleré, Marina Bataller Fernández
Funding agency: Instituto de Salud Carlos III
Funding: 183920
Reference: PI20/00556
Duration: 01/01/2021 - 30/06/2025

Drug-screen against novel proteins involved in cancer resistance

IP: Matilde Lleonart Pajarin
Collaborators: Almudena Sanchez Garcia, Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 50649.27
Reference: VHIR/BEQUESPREDOC/2019/SANCHEZ
Duration: 14/09/2020 - 13/09/2023

Related news

The Biomedical Research in Cancer Stem Cells group at VHIR has identified a new therapeutic target and is working to find new therapies for this type of tumor.

On World Cancer Research Day, we highlight the oncology research model of the Vall d'Hebron Campus that allows laboratory results to be transferred as quickly as possible to clinical practice.

Vall d’Hebron ha celebrat avui la Jornada del Dia Mundial contra el Càncer, una malaltia cada cop més freqüent que patiran al llarg de la vida un de cada dos homes i una de cada tres dones del nostre entorn.

Related professionals

Mireia Verdaguer Tremolosa

Mireia Verdaguer Tremolosa

Research technician
General Surgery
Read more
Pablo Vilalta Gras

Pablo Vilalta Gras

Zelador/a
General Services and Infrastructures Unit
Manager
Read more
Carmen Sanchez Suarez

Carmen Sanchez Suarez

Molecular Medical Imaging
Read more
Laura Rubio Guerrero

Laura Rubio Guerrero

Medium Grade Technician
Purchase and Biddings Unit
Finance Directorate
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.